Tofacitinib Citrate (BioDeep_00000759399)
代谢物信息卡片
Tofacitinib (CP-690550) Citrate
化学式: C22H28N6O8 (504.1968528)
中文名称: 枸橼酸托法替尼
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
InChI: /m1./s1
描述信息
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors > D000075242 - Janus Kinase Inhibitors
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C172200 - JAK Inhibitor
同义名列表
数据库引用编号
5 个数据库交叉引用编号
- ChEBI: CHEBI:71197
- KEGGdrug: D09783
- PubChem: 10174505
- ChEMBL: CHEMBL2103743
- CAS: 540737-29-9
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Qianqian Dai, Yanfeng Zhang, Qian Liu, Chijin Zhang. Efficacy and safety of tofacitinib for chronic plaque psoriasis and psoriatic arthritis: a systematic review and meta-analysis of randomized controlled trials.
Clinical rheumatology.
2024 May; 43(5):1605-1613. doi:
10.1007/s10067-024-06940-5. [PMID: 38517652] - Enrica Flori, Alessia Cavallo, Sarah Mosca, Daniela Kovacs, Carlo Cota, Marco Zaccarini, Anna Di Nardo, Grazia Bottillo, Miriam Maiellaro, Emanuela Camera, Giorgia Cardinali. JAK/STAT Inhibition Normalizes Lipid Composition in 3D Human Epidermal Equivalents Challenged with Th2 Cytokines.
Cells.
2024 Apr; 13(9):. doi:
10.3390/cells13090760. [PMID: 38727296] - Ronglin Gao, Jincheng Pu, Yanqing Wang, Zhenzhen Wu, Yuanyuan Liang, Jiamin Song, Shengnan Pan, Fang Han, Lufei Yang, Xianghuai Xu, Jianping Tang, Xuan Wang. Tofacitinib in the treatment of primary Sjögren's syndrome-associated interstitial lung disease: study protocol for a prospective, randomized, controlled and open-label trial.
BMC pulmonary medicine.
2023 Nov; 23(1):473. doi:
10.1186/s12890-023-02774-0. [PMID: 38007449] - Ying-Jun Wang, Hai-Zhen Hui, Jia-Rong Cheng, Han Mao, Qing-Chun Diao, Bing-Jun Shi. Improvement of Refractory Chronic Actinic Dermatitis During Tofacitinib Treatment.
American journal of therapeutics.
2023 Nov; 30(6):e547-e548. doi:
10.1097/mjt.0000000000001616. [PMID: 36856587] - Hongda Li, Honglei Wang, Guizhi Qiao, Yongxia Liu, Furen Zhang, Futang Pan. Concurrent bullous pemphigoid and psoriasis vulgaris successfully treated with Janus kinase inhibitor tofacitinib: A case report and review of the literature.
International immunopharmacology.
2023 Sep; 122(?):110591. doi:
10.1016/j.intimp.2023.110591. [PMID: 37441809] - Maria Pia Adorni, Bianca Papotti, Maria Orietta Borghi, Elena Raschi, Francesca Zimetti, Franco Bernini, Pier Luigi Meroni, Nicoletta Ronda. Effect of the JAK/STAT Inhibitor Tofacitinib on Macrophage Cholesterol Metabolism.
International journal of molecular sciences.
2023 Aug; 24(16):. doi:
10.3390/ijms241612571. [PMID: 37628747] - Zong Jiang, Xiaoling Yao, Fang Tang, Wukai Ma. Case report: Successful treatment of anti-MDA5-positive to negative dermatomyositis-associated interstitial lung disease with the JAK inhibitor tofacitinib.
Immunity, inflammation and disease.
2023 06; 11(6):e897. doi:
10.1002/iid3.897. [PMID: 37382261] - Yeneng Guan, Aqin Yan, Wei Qiang, Rui Ruan, Chaobo Yang, Kai Ma, Hongmei Sun, Mingxing Liu, Hongda Zhu. Selective Delivery of Tofacitinib Citrate to Hair Follicles Using Lipid-Coated Calcium Carbonate Nanocarrier Controls Chemotherapy-Induced Alopecia Areata.
International journal of molecular sciences.
2023 May; 24(9):. doi:
10.3390/ijms24098427. [PMID: 37176141] - Heba Hesham, Mai Rady, Rania M Hathout, Mohammad Abdel-Halim, Samar Mansour. The skin delivery of tofacitinib citrate using transethosomes and hybridized ethosomes/nanostructured lipid carriers for vitiligo therapy: Dermatopharmacokinetics and in vivo assays.
International journal of pharmaceutics.
2022 Dec; 629(?):122387. doi:
10.1016/j.ijpharm.2022.122387. [PMID: 36375683] - Hema Murugesan, Gauthaman Cs, H Sadiqa Nasreen, Sham Santhanam, Gowrishankar M, Sailatha Ravi, Sharanya Shre Es. An Evaluation of Efficacy and Safety of Tofacitinib, A JAK Inhibitor in the Management of Hospitalized Patients with Mild to Moderate COVID-19 - An Open-Label Randomized Controlled Study.
The Journal of the Association of Physicians of India.
2022 Dec; 69(12):11-12. doi:
NULL. [PMID: 35057599] - Monika Czókolyová, Attila Hamar, Anita Pusztai, Gábor Tajti, Edit Végh, Zsófia Pethő, Nóra Bodnár, Ágnes Horváth, Boglárka Soós, Szilvia Szamosi, Anita Szentpéteri, Ildikó Seres, Mariann Harangi, György Paragh, György Kerekes, Levente Bodoki, Andrea Domján, Katalin Hodosi, Tamás Seres, György Panyi, Zoltán Szekanecz, Gabriella Szűcs. Effects of One-Year Tofacitinib Therapy on Lipids and Adipokines in Association with Vascular Pathophysiology in Rheumatoid Arthritis.
Biomolecules.
2022 Oct; 12(10):. doi:
10.3390/biom12101483. [PMID: 36291691] - Li Lin, Yuan Wang, Sennan Shao, Wen Lin, Dan Huang, Yue Dai, Yufeng Xia. Herb-drug interaction between Shaoyao-Gancao-Fuzi decoction and tofacitinib via CYP450 enzymes.
Journal of ethnopharmacology.
2022 Sep; 295(?):115437. doi:
10.1016/j.jep.2022.115437. [PMID: 35667582] - Zhongnan Xu, Yanli Wang, Zhengzhi Liu, Renjie Zhang, Yannan Zhou, Jing Yu, Jing Lan, Wenzhong Liang, Guangwen Liu, Xinyao Qu, Jiahui Chen, Zhengjie Su, Shuang Yu, Yang Cheng, Wanhua Wang, Qing Ren, Qiaohuan Deng, Yicheng Zhao, Haimiao Yang. A randomized, crossover, phase I clinical study to evaluate bioequivalence and safety of tofacitinib and Xeljanz® in Chinese healthy subjects.
International immunopharmacology.
2022 Aug; 109(?):108780. doi:
10.1016/j.intimp.2022.108780. [PMID: 35461158] - Ziteng Wang, Eric Chun Yong Chan. Physiologically-Based Pharmacokinetic Modelling to Investigate Baricitinib and Tofacitinib Dosing Recommendations for COVID-19 in Geriatrics.
Clinical pharmacology and therapeutics.
2022 Aug; 112(2):291-296. doi:
10.1002/cpt.2600. [PMID: 35380176] - Arnab Mukherjee, Shinichi Tsuchiwata, Timothy Nicholas, Jack A Cook, Irene Modesto, Chinyu Su, Geert R D'Haens, William J Sandborn. Exposure-Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance Studies.
Clinical pharmacology and therapeutics.
2022 Jul; 112(1):90-100. doi:
10.1002/cpt.2601. [PMID: 35380740] - Daisuke Hiraoka, Jun Ishizaki, Kenta Horie, Takuya Matsumoto, Koichiro Suemori, Katsuto Takenaka, Hitoshi Hasegawa. A case of clinically amyopathic dermatomyositis that was refractory to intensive immunosuppressive therapy including tofacitinib, but successfully treated with plasma exchange therapy.
Modern rheumatology case reports.
2022 06; 6(2):194-198. doi:
10.1093/mrcr/rxab054. [PMID: 34984465] - Yueting Li, Yihan Cao, Chen Li, Wen Zhang. Response to: 'Off-label use of tofacitinib: a potential treatment option for SAPHO syndrome' by Xie et al.
Annals of the rheumatic diseases.
2022 06; 81(6):e92. doi:
10.1136/annrheumdis-2020-217956. [PMID: 32527867] - Kazuma Ino, Nana Kinoshita, Yoshiyuki Arinuma, Yu Matsueda, Kunihiro Yamaoka. Improvements in PET/CT results and serum cytokine profile of HLA-B52-positive patients with Takayasu's arteritis and ulcerative colitis post-tofacitinib.
Clinical and experimental rheumatology.
2022 05; 40(4):849-850. doi:
10.55563/clinexprheumatol/i9chku. [PMID: 34251319] - Jiaxing Zhao, Bing Zhang, Qing Mao, Kunqi Ping, Peng Zhang, Fengwei Lin, Dan Liu, Yao Feng, Ming Sun, Yan Zhang, Qiu Hua Li, Tingjian Zhang, Yanhua Mou, Shaojie Wang. Discovery of a Colon-Targeted Azo Prodrug of Tofacitinib through the Establishment of Colon-Specific Delivery Systems Constructed by 5-ASA-PABA-MAC and 5-ASA-PABA-Diamine for the Treatment of Ulcerative Colitis.
Journal of medicinal chemistry.
2022 03; 65(6):4926-4948. doi:
10.1021/acs.jmedchem.1c02166. [PMID: 35275619] - Sepideh Zununi Vahed, Seyed Mahdi Hosseiniyan Khatibi, Elham Ahmadian, Mohammadreza Ardalan. Targeting chronic COVID-19 lung injury; Tofacitinib can be used against tissue-resident memory T cells.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
2022 Mar; 147(?):112614. doi:
10.1016/j.biopha.2022.112614. [PMID: 34995938] - Poh Lin Pauline Chan Ng, Archana Mopur, Daniel Yam Thiam Goh, Mahesh Babu Ramamurthy, Michael Teik Chung Lim, Lee Kean Lim, Pei Ling Ooi, Elizabeth Youning Ang. Janus kinase inhibition in induction treatment of anti-MDA5 juvenile dermatomyositis-associated rapidly progressive interstitial lung disease.
International journal of rheumatic diseases.
2022 Feb; 25(2):228-231. doi:
10.1111/1756-185x.14258. [PMID: 34882988] - Steven R Ytterberg, Deepak L Bhatt, Ted R Mikuls, Gary G Koch, Roy Fleischmann, Jose L Rivas, Rebecca Germino, Sujatha Menon, Yanhui Sun, Cunshan Wang, Andrea B Shapiro, Keith S Kanik, Carol A Connell. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.
The New England journal of medicine.
2022 01; 386(4):316-326. doi:
10.1056/nejmoa2109927. [PMID: 35081280] - Haoyuan Song, Chao Liu, Jiuheng Ruan, Degong Yang, Ting Zhong, Yuxue Liu, Liang Fang. Effect of the combination of permeation enhancer and ion-pairs strategies on transdermal delivery of tofacitinib.
International journal of pharmaceutics.
2022 Jan; 611(?):121190. doi:
10.1016/j.ijpharm.2021.121190. [PMID: 34662645] - Alessia Alunno, Aurélie Najm, Pedro M Machado, Heidi Bertheussen, Gerd-Rüdiger R Burmester, Francesco Carubbi, Gabriele De Marco, Roberto Giacomelli, Olivier Hermine, John D Isaacs, Isabelle Koné-Paut, César Magro-Checa, Iain B McInnes, Pier Luigi Meroni, Luca Quartuccio, A V Ramanan, Manuel Ramos-Casals, Javier Rodríguez Carrio, Hendrik Schulze-Koops, Tanja A Stamm, Sander W Tas, Benjamin Terrier, Dennis G McGonagle, Xavier Mariette. 2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19.
Annals of the rheumatic diseases.
2022 01; 81(1):34-40. doi:
10.1136/annrheumdis-2021-221366. [PMID: 34620584] - Frank L van de Veerdonk, Evangelos Giamarellos-Bourboulis, Peter Pickkers, Lennie Derde, Helen Leavis, Reinout van Crevel, Job J Engel, W Joost Wiersinga, Alexander P J Vlaar, Manu Shankar-Hari, Tom van der Poll, Marc Bonten, Derek C Angus, Jos W M van der Meer, Mihai G Netea. A guide to immunotherapy for COVID-19.
Nature medicine.
2022 01; 28(1):39-50. doi:
10.1038/s41591-021-01643-9. [PMID: 35064248] - Alexandre Naime Barbosa, Antonio Silvinato, Hélio Bacha, Idevaldo Floriano, Suzana Tanni, Wanderley Bernardo. Use of disease-modifying drugs (tocilizumab, tofacitinib, and baricitinib-a biological or synthetic target specific) in patients hospitalized with COVID-19.
Revista da Associacao Medica Brasileira (1992).
2022 01; 68(1):3-8. doi:
10.1590/1806-9282.2022d681. [PMID: 35239928] - Refaa Alajmi, Munirah Alabdulhadi, Ali A Alali, Mohammad Shehab. Tofacitinib for a Child with Refractory Steroid-Dependent Ulcerative Colitis: A Case Report and Review of the Literature.
The American journal of case reports.
2021 Nov; 22(?):e934460. doi:
10.12659/ajcr.934460. [PMID: 34767543] - Sz-Tsan Wang, Chih-Wei Tseng, Chia-Wen Hsu, Chien-Hsueh Tung, Kuang-Yung Huang, Ming-Chi Lu, Ning-Sheng Lai. Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib.
International journal of rheumatic diseases.
2021 Nov; 24(11):1362-1369. doi:
10.1111/1756-185x.14217. [PMID: 34506078] - Ashish Sharma, Mohammad Ali. Case Report: Home-based Management of Severe COVID-19 with Low-dose Tofacitinib.
The American journal of tropical medicine and hygiene.
2021 Oct; 105(6):1472-1475. doi:
10.4269/ajtmh.21-0737. [PMID: 34607309] - Q Sun, B Fu, S Li, H Fang, J Qiao. Efficacy of tofacitinib in Kimura's disease in a patient with concomitant atopic dermatitis.
Clinical and experimental dermatology.
2021 Oct; 46(7):1336-1338. doi:
10.1111/ced.14671. [PMID: 33837590] - Ching-Yi Chen, Wang-Chun Chen, Chi-Kuei Hsu, Chien-Ming Chao, Chih-Cheng Lai. Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: A systematic review and meta-analysis of randomized controlled trials.
International immunopharmacology.
2021 Oct; 99(?):108027. doi:
10.1016/j.intimp.2021.108027. [PMID: 34343937] - Steven Y C Tong, Neta Petersiel. Tofacitinib reduced death or respiratory failure at 28 d in patients hospitalized with COVID-19 pneumonia.
Annals of internal medicine.
2021 10; 174(10):JC111. doi:
10.7326/acpj202110190-111. [PMID: 34606317] - Naoko Okiyama, Yuki Ichimura, Miwako Shobo, Ryota Tanaka, Noriko Kubota, Akimasa Saito, Yosuke Ishitsuka, Rei Watanabe, Yasuhiro Fujisawa, Yoshiyuki Nakamura, Akihiro Murakami, Hisako Kayama, Kiyoshi Takeda, Manabu Fujimoto. Immune response to dermatomyositis-specific autoantigen, transcriptional intermediary factor 1γ can result in experimental myositis.
Annals of the rheumatic diseases.
2021 09; 80(9):1201-1208. doi:
10.1136/annrheumdis-2020-218661. [PMID: 33811031] - Vivien Wai Yun Lai, Laita Bokhari, Rodney Sinclair. Sublingual tofacitinib for alopecia areata: a roll-over pilot clinical trial and analysis of pharmacokinetics.
International journal of dermatology.
2021 Sep; 60(9):1135-1139. doi:
10.1111/ijd.15657. [PMID: 34008179] - Mahta Mortezavi, Sujatha Menon, Kristen Lee, Jose Rivas. Use of Tofacitinib in the Context of COVID-19 Vaccination: Comment on the American College of Rheumatology Clinical Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases.
Arthritis & rheumatology (Hoboken, N.J.).
2021 09; 73(9):1768-1769. doi:
10.1002/art.41806. [PMID: 34042319] - Oleg Melikhov, Tatiana Kruglova, Karine Lytkina, Georgy Melkonyan, Elena Prokhorovich, Gleb Putsman, Grigory Rodoman, Arkady Vertkin, Alena Zagrebneva, Justin Stebbing. Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals.
Annals of the rheumatic diseases.
2021 09; 80(9):1245-1246. doi:
10.1136/annrheumdis-2021-220049. [PMID: 34099486] - Karol Palasiewicz, Sadiq Umar, Bianca Romay, Ryan K Zomorrodi, Shiva Shahrara. Tofacitinib therapy intercepts macrophage metabolic reprogramming instigated by SARS-CoV-2 Spike protein.
European journal of immunology.
2021 09; 51(9):2330-2340. doi:
10.1002/eji.202049159. [PMID: 34107055] - Paola Di Benedetto, Piero Ruscitti, Onorina Berardicurti, Noemi Panzera, Nicolò Grazia, Mauro Di Vito Nolfi, Barbara Di Francesco, Luca Navarini, Antonio Maurizi, Nadia Rucci, Anna Maria Teti, Francesca Zazzeroni, Giuliana Guggino, Francesco Ciccia, Vincenza Dolo, Edoardo Alesse, Paola Cipriani, Roberto Giacomelli. Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis.
Arthritis research & therapy.
2021 08; 23(1):213. doi:
10.1186/s13075-021-02587-8. [PMID: 34391476] - Eric J Rubin, Lindsey R Baden, Stephen Morrissey. Audio Interview: Monoclonal Antibodies and Booster Shots.
The New England journal of medicine.
2021 Aug; 385(7):e29. doi:
10.1056/nejme2113398. [PMID: 34379932] - Roman Maslennikov, Vladimir Ivashkin, Ekaterina Vasilieva, Maxim Chipurik, Polina Semikova, Victoria Semenets, Tatyana Russkova, Anna Levshina, Diana Grigoriadis, Shamil Magomedov, Irina Efremova, Natiya Dzhakhaya. Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19.
Pulmonary pharmacology & therapeutics.
2021 08; 69(?):102039. doi:
10.1016/j.pupt.2021.102039. [PMID: 34023513] - Patrícia O Guimarães, Daniel Quirk, Remo H Furtado, Lilia N Maia, José F Saraiva, Murillo O Antunes, Roberto Kalil Filho, Vagner M Junior, Alexandre M Soeiro, Alexandre P Tognon, Viviane C Veiga, Priscilla A Martins, Diogo D F Moia, Bruna S Sampaio, Silvia R L Assis, Ronaldo V P Soares, Luciana P A Piano, Kleber Castilho, Roberta G R A P Momesso, Frederico Monfardini, Helio P Guimarães, Dario Ponce de Leon, Majori Dulcine, Marcia R T Pinheiro, Levent M Gunay, J Jasper Deuring, Luiz V Rizzo, Tamas Koncz, Otavio Berwanger. Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia.
The New England journal of medicine.
2021 07; 385(5):406-415. doi:
10.1056/nejmoa2101643. [PMID: 34133856] - Philipp A Reuken, Niels Teich, Andreas Stallmach. Safety of Tofacitinib in the COVID-19 Pandemic-Enough Is Not Enough.
Inflammatory bowel diseases.
2021 07; 27(8):e89. doi:
10.1093/ibd/izab051. [PMID: 33783508] - Paqui G Traves, Bernard Murray, Federico Campigotto, René Galien, Amy Meng, Julie A Di Paolo. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
Annals of the rheumatic diseases.
2021 07; 80(7):865-875. doi:
10.1136/annrheumdis-2020-219012. [PMID: 33741556] - Gentle Sunder Shrestha, Bidesh Bista, Ashesh Dhungana, Nimesh Poudel, Shraddha Bhattarai, Manjit Shrestha, Sandip Bhandari, Binit Vaidya. Tofacitinib as an Adjunct Immunomodulator for Treatment of a Patient with Severe COVID-19: A Case Report.
JNMA; journal of the Nepal Medical Association.
2021 Jul; 59(238):593-596. doi:
10.31729/jnma.6680. [PMID: 34508399] - S Berbert Ferreira, M F R Gavazzoni Dias, R Berbert Ferreira, A C Neves Neto, R M Trüeb, O Lupi. Rapidly progressive alopecia areata totalis in a COVID-19 patient, unresponsive to tofacitinib.
Journal of the European Academy of Dermatology and Venereology : JEADV.
2021 Jul; 35(7):e411-e412. doi:
10.1111/jdv.17170. [PMID: 33587766] - Eric J Rubin, Lindsey R Baden, Julie R Ingelfinger, Stephen Morrissey. Audio Interview: Covid-19 in Children.
The New England journal of medicine.
2021 06; 384(24):e108. doi:
10.1056/nejme2110211. [PMID: 34133868] - Cláudia Monfroni Rocha, Alessandro Menna Alves, Beatriz Fabris Bettanin, Fernanda Majolo, Matthias Gehringer, Stefan Laufer, Márcia Inês Goettert. Current jakinibs for the treatment of rheumatoid arthritis: a systematic review.
Inflammopharmacology.
2021 Jun; 29(3):595-615. doi:
10.1007/s10787-021-00822-x. [PMID: 34046798] - Bruce E Sands, Jean-Frédéric Colombel, Christina Ha, Michel Farnier, Alessandro Armuzzi, Daniel Quirk, Gary S Friedman, Kenneth Kwok, Leonardo Salese, Chinyu Su, Pam R Taub. Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib-Implications for Cardiovascular Risk and Patient Management.
Inflammatory bowel diseases.
2021 05; 27(6):797-808. doi:
10.1093/ibd/izaa227. [PMID: 32870265] - O G Artamonova, A E Karamova, A A Nikonorov, D A Verbenko, E L Vasileva, A A Kubanov. The Effect of Janus Kinase Inhibitors and Phosphodiesterase-4 Inhibitors on Skin and Plasma Cytokine Levels in Patients with Psoriasis.
Bulletin of experimental biology and medicine.
2021 May; 171(2):208-211. doi:
10.1007/s10517-021-05196-2. [PMID: 34173094] - Xin Li, Lihua Liu, Yang Deng, Yuan Li, Ping Zhang, Yangyang Wang, Bing Xu, Jie Feng, Lu Huang. Pharmacokinetics and Bioequivalence of 2 Immediate-Release Tofacitinib Tablet Formulations in Chinese Healthy Volunteers Under Fasting and Fed Conditions.
Clinical pharmacology in drug development.
2021 05; 10(5):535-541. doi:
10.1002/cpdd.864. [PMID: 32770665] - Anna Materna-Kiryluk, Agnieszka Pollak, Karol Gawalski, Aleksandra Szczawinska-Poplonyk, Zuzanna Rydzynska, Anna Sosnowska, Bożena Cukrowska, Piotr Gasperowicz, Ewa Konopka, Barbara Pietrucha, Tomasz M Grzywa, Magdalena Banaszak-Ziemska, Marek Niedziela, Jolanta Skalska-Sadowska, Piotr Stawiński, Dariusz Śladowski, Dominika Nowis, Rafal Ploski. Mosaic IL6ST variant inducing constitutive GP130 cytokine receptor signaling as a cause of neonatal onset immunodeficiency with autoinflammation and dysmorphy.
Human molecular genetics.
2021 04; 30(3-4):226-233. doi:
10.1093/hmg/ddab035. [PMID: 33517393] - Bin Yu, Xiaoru Wang, Yaru Yang, Chao Lu, Wei Hu, Xueyuan Zhang. Evaluation of tofacitinib citrate bioequivalence based on pharmacokinetic parameters in healthy Chinese subjects.
International journal of clinical pharmacology and therapeutics.
2021 Apr; 59(4):343-352. doi:
10.5414/cp203751. [PMID: 33433317] - Rahul Pandey, Marina Bakay, Bryan P Strenkowski, Heather S Hain, Hakon Hakonarson. JAK/STAT inhibitor therapy partially rescues the lipodystrophic autoimmune phenotype in Clec16a KO mice.
Scientific reports.
2021 04; 11(1):7372. doi:
10.1038/s41598-021-86493-8. [PMID: 33795715] - Manasi Agrawal, Erica J Brenner, Xian Zhang, Irene Modesto, John Woolcott, Ryan C Ungaro, Jean-Frederic Colombel, Michael D Kappelman. Characteristics and Outcomes of IBD Patients with COVID-19 on Tofacitinib Therapy in the SECURE-IBD Registry.
Inflammatory bowel diseases.
2021 03; 27(4):585-589. doi:
10.1093/ibd/izaa303. [PMID: 33325523] - Muazzez Cigdem Oba, Ozge Askin, Ozlem Balci Ekmekci, Server Serdaroglu. Correlation between serum granulysin level and clinical activity in patients with alopecia areata before and after tofacitinib therapy.
Journal of cosmetic dermatology.
2021 Mar; 20(3):971-975. doi:
10.1111/jocd.13598. [PMID: 32808476] - Özge Aşkın, Defne Özkoca, Tuğba Kevser Uzunçakmak, Server Serdaroğlu. Evaluation of the alopecia areata patients on tofacitinib treatment during the COVID-19 pandemic.
Dermatologic therapy.
2021 03; 34(2):e14746. doi:
10.1111/dth.14746. [PMID: 33405372] - Jasmijn A M Sleutjes, Annemarie C de Vries, C Janneke van der Woude, Jeanine E Roeters van Lennep. Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib-Implications for Cardiovascular Risk and Patient Management.
Inflammatory bowel diseases.
2021 02; 27(3):e25. doi:
10.1093/ibd/izaa295. [PMID: 33155646] - Lennart R S Huizing, James McDuffie, Filip Cuyckens, Marjolein van Heerden, Tatiana Koudriakova, Ron M A Heeren, Rob J Vreeken. Quantitative Mass Spectrometry Imaging to Study Drug Distribution in the Intestine Following Oral Dosing.
Analytical chemistry.
2021 02; 93(4):2144-2151. doi:
10.1021/acs.analchem.0c03956. [PMID: 33470103] - Daekwon Bae, Youngil Choi, Jiyoung Lee, Nina Ha, Donghyeon Suh, Jiyeon Baek, Jinsol Park, Woochan Son. M-134, a novel HDAC6-selective inhibitor, markedly improved arthritic severity in a rodent model of rheumatoid arthritis when combined with tofacitinib.
Pharmacological reports : PR.
2021 Feb; 73(1):185-201. doi:
10.1007/s43440-020-00188-x. [PMID: 33188511] - Arindam Banerjee, Rudra Prosad Goswami, Moumita Chatterjee. Network theoretic analysis of JAK/STAT pathway and extrapolation to drugs and viruses including COVID-19.
Scientific reports.
2021 01; 11(1):2512. doi:
10.1038/s41598-021-82139-x. [PMID: 33510353] - Alexis Gonneaud, Naomie Turgeon, Francois-Michel Boisvert, Francois Boudreau, Claude Asselin. JAK-STAT Pathway Inhibition Partially Restores Intestinal Homeostasis in Hdac1- and Hdac2-Intestinal Epithelial Cell-Deficient Mice.
Cells.
2021 01; 10(2):. doi:
10.3390/cells10020224. [PMID: 33498747] - Qiao Zhou, Jayakumar Vadakekolathu, Abdulla Watad, Kassem Sharif, Tobias Russell, Hannah Rowe, Almas Khan, Peter A Millner, Peter Loughenbury, Abhay Rao, Robert Dunsmuir, Jake Timothy, Giovanni Damiani, Paolo D M Pigatto, Piergiorgio Malagoli, Giuseppe Banfi, Yasser M El-Sherbiny, Charlie Bridgewood, Dennis McGonagle. SARS-CoV-2 Infection Induces Psoriatic Arthritis Flares and Enthesis Resident Plasmacytoid Dendritic Cell Type-1 Interferon Inhibition by JAK Antagonism Offer Novel Spondyloarthritis Pathogenesis Insights.
Frontiers in immunology.
2021; 12(?):635018. doi:
10.3389/fimmu.2021.635018. [PMID: 33936047] - Qing Yan, Weiwei Chen, Hua Song, Xianming Long, Zhuoya Zhang, Xiaojun Tang, Hongwei Chen, He Lin, Lingyun Sun. Tofacitinib Ameliorates Lupus Through Suppression of T Cell Activation Mediated by TGF-Beta Type I Receptor.
Frontiers in immunology.
2021; 12(?):675542. doi:
10.3389/fimmu.2021.675542. [PMID: 34394075] - Chen Li, Zhaohui Li, Yihan Cao, Li Li, Feng Li, Yueting Li, Dingkun Xiong, Xia Wu, Wen Zhang, Xiaofeng Zeng. Tofacitinib for the Treatment of Nail Lesions and Palmoplantar Pustulosis in Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis Syndrome.
JAMA dermatology.
2021 01; 157(1):74-78. doi:
10.1001/jamadermatol.2020.3095. [PMID: 32997094] - Cristian Quintana-Ortega, Agustín Remesal, Marta Ruiz de Valbuena, Olga de la Serna, María Laplaza-González, Elena Álvarez-Rojas, Clara Udaondo, Rosa Alcobendas, Sara Murias. Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report.
Modern rheumatology case reports.
2021 01; 5(1):101-107. doi:
10.1080/24725625.2020.1832755. [PMID: 33019894] - Yang Yun, Jingyu Chen, Xuejiao Wang, Yingzhuo Li, Zhifan Hu, Pingting Yang, Ling Qin. Tofacitinib Ameliorates Lipopolysaccharide-Induced Acute Kidney Injury by Blocking the JAK-STAT1/STAT3 Signaling Pathway.
BioMed research international.
2021; 2021(?):8877056. doi:
10.1155/2021/8877056. [PMID: 33511217] - Bo Wang, Jiquan Shen, Quan Zhou, Deru Meng, Youwu He, Feifei Chen, Shuanghu Wang, Weiping Ji. Effects of naringenin on the pharmacokinetics of tofacitinib in rats.
Pharmaceutical biology.
2020 Dec; 58(1):225-230. doi:
10.1080/13880209.2020.1738504. [PMID: 32202190] - Ivan Haralampiev, Diego Javier Alonso de Armiño, Meike Luck, Markus Fischer, Tobias Abel, Daniel Huster, Santiago Di Lella, Holger A Scheidt, Peter Müller. Interaction of the small-molecule kinase inhibitors tofacitinib and lapatinib with membranes.
Biochimica et biophysica acta. Biomembranes.
2020 11; 1862(11):183414. doi:
10.1016/j.bbamem.2020.183414. [PMID: 32710852] - Sherihan Salaheldin Abdelhamid Ibrahim, Mona Abdelrazek Salama, Eman Selima, Rowaida Refaat Shehata. Sitagliptin and tofacitinib ameliorate adjuvant induced arthritis via modulating the cross talk between JAK/STAT and TLR-4/NF-κB signaling pathways.
Life sciences.
2020 Nov; 260(?):118261. doi:
10.1016/j.lfs.2020.118261. [PMID: 32795539] - Conor N Gruber, Jorg J A Calis, Sofija Buta, Gilad Evrony, Jerome C Martin, Skyler A Uhl, Rachel Caron, Lauren Jarchin, David Dunkin, Robert Phelps, Bryn D Webb, Jeffrey M Saland, Miriam Merad, Jordan S Orange, Emily M Mace, Brad R Rosenberg, Bruce D Gelb, Dusan Bogunovic. Complex Autoinflammatory Syndrome Unveils Fundamental Principles of JAK1 Kinase Transcriptional and Biochemical Function.
Immunity.
2020 09; 53(3):672-684.e11. doi:
10.1016/j.immuni.2020.07.006. [PMID: 32750333] - Yueting Li, Jianwei Huo, Yihan Cao, Meiyan Yu, Yanan Zhang, Zhaohui Li, Chen Li, Wen Zhang. Efficacy of tofacitinib in synovitis, acne, pustulosis, hyperostosis and osteitis syndrome: a pilot study with clinical and MRI evaluation.
Annals of the rheumatic diseases.
2020 09; 79(9):1255-1257. doi:
10.1136/annrheumdis-2020-217250. [PMID: 32332076] - Florence Enjalbert, Priya Dewan, Matthew P Caley, Eleri M Jones, Mary A Morse, David P Kelsell, Anton J Enright, Edel A O'Toole. 3D model of harlequin ichthyosis reveals inflammatory therapeutic targets.
The Journal of clinical investigation.
2020 09; 130(9):4798-4810. doi:
10.1172/jci132987. [PMID: 32544098] - Carlo Salvarani, Gianluigi Bajocchi, Pamela Mancuso, Elena Galli, Francesco Muratore, Luigi Boiardi, Mariagrazia Catanoso, Nicolò Pipitone, Giulia Cassone, Nicolò Girolimetto, Stefania Croci, Luca Cimino, Federeica Gradellini, Marina Beltrami, Vito Di Lernia, Giovammi Dolci, Marco Massari, Anna Maria Marata, Massimo Costantini, Paolo Giorgi Rossi. Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: a population-based study.
Annals of the rheumatic diseases.
2020 07; 79(7):986-988. doi:
10.1136/annrheumdis-2020-217903. [PMID: 32467245] - Jeffrey Jacobs, Kindra Clark-Snustad, Scott Lee. Case Report of a SARS-CoV-2 Infection in a Patient With Ulcerative Colitis on Tofacitinib.
Inflammatory bowel diseases.
2020 06; 26(7):e64. doi:
10.1093/ibd/izaa093. [PMID: 32342098] - Danielle Peterson, William Damsky, Brett King. The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Journal of the American Academy of Dermatology.
2020 06; 82(6):e223-e226. doi:
10.1016/j.jaad.2020.03.099. [PMID: 32278797] - Parambir S Dulai, Robert Battat, Maria Barsky, Nghia H Nguyen, Christopher Ma, Neeraj Narula, Mahmoud Mosli, Niels Vande Casteele, Brigid S Boland, Larry Prokop, M Hassan Murad, Geert D'Haens, Brian G Feagan, William J Sandborn, Vipul Jairath, Siddharth Singh. Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors.
The American journal of gastroenterology.
2020 06; 115(6):885-894. doi:
10.14309/ajg.0000000000000596. [PMID: 32384283] - Ashok Zakkula, Shobha Pulipati, Sreekanth Dittakavi, Ram Murthi Bestha, Mohd Zainuddin, Ravi Kumar Trivedi, Ramesh Mullangi. Development and Validation of an HPLC Method for Quantification of Filgotinib, a Novel JAK-1 Inhibitor in Mice Plasma: Application to a Pharmacokinetic Study.
Drug research.
2020 May; 70(5):233-238. doi:
10.1055/a-1141-3475. [PMID: 32289835] - Qiying Shen, Huan Shu, Xiaoling Xu, Gaofeng Shu, Yongzhong Du, Xiaoying Ying. Tofacitinib citrate-based liposomes for effective treatment of rheumatoid arthritis.
Die Pharmazie.
2020 04; 75(4):131-135. doi:
10.1691/ph.2020.9154. [PMID: 32295688] - Izumi Itoh, Kenji Kasuno, Chie Yamamoto, Naoki Takahashi, Hisanori Shimizu, Tomohiro Ojima, Seigaku Hayashi, Hideki Kimura, Masayuki Iwano. IgA Vasculitis Developed as an Adverse Effect of Tofacitinib Taken for Rheumatoid Arthritis.
Internal medicine (Tokyo, Japan).
2020 Mar; 59(6):817-821. doi:
10.2169/internalmedicine.3668-19. [PMID: 31813912] - Emely Verweyen, Dirk Holzinger, Toni Weinhage, Claas Hinze, Helmut Wittkowski, Peter Pickkers, Sabrin Albeituni, Katherine Verbist, Kim E Nichols, Grant Schulert, Alexei Grom, Dirk Foell, Christoph Kessel. Synergistic Signaling of TLR and IFNα/β Facilitates Escape of IL-18 Expression from Endotoxin Tolerance.
American journal of respiratory and critical care medicine.
2020 03; 201(5):526-539. doi:
10.1164/rccm.201903-0659oc. [PMID: 31710506] - Mohamed-Eslam F Mohamed, Denise Beck, Heidi S Camp, Ahmed A Othman. Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure-Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib.
Journal of clinical pharmacology.
2020 02; 60(2):188-197. doi:
10.1002/jcph.1513. [PMID: 31448433] - So Miyoshi, Sriram Krishnaswami, Shigeyuki Toyoizumi, Hiroyuki Nakamura, Samuel H Zwillich. Phase 1 Dose-Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Japanese Healthy Volunteers.
Clinical pharmacology in drug development.
2020 01; 9(1):11-20. doi:
10.1002/cpdd.741. [PMID: 31713350] - Bruce E Sands, Pam R Taub, Alessandro Armuzzi, Gary S Friedman, Michele Moscariello, Nervin Lawendy, Ronald D Pedersen, Gary Chan, Chudy I Nduaka, Daniel Quirk, Leonardo Salese, Chinyu Su, Brian G Feagan. Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
2020 01; 18(1):123-132.e3. doi:
10.1016/j.cgh.2019.04.059. [PMID: 31077827] - Hauwa'u Yakubu Bako, Mohammed Auwal Ibrahim, Muhammad Sani Isah, Sani Ibrahim. Inhibition of JAK-STAT and NF-κB signalling systems could be a novel therapeutic target against insulin resistance and type 2 diabetes.
Life sciences.
2019 Dec; 239(?):117045. doi:
10.1016/j.lfs.2019.117045. [PMID: 31730866] - Sanchita Raychaudhuri, Christine Abria, Zachary T Harmany, Charles M Smith, Smriti Kundu-Raychaudhuri, Siba P Raychaudhuri, Abhijit J Chaudhari. Quantitative tracking of inflammatory activity at the peak and trough plasma levels of tofacitinib, a Janus kinase inhibitor, via in vivo 18 F-FDG PET.
International journal of rheumatic diseases.
2019 Dec; 22(12):2165-2169. doi:
10.1111/1756-185x.13732. [PMID: 31659868] - Martin E Dowty, Tsung H Lin, Michael I Jesson, Martin Hegen, David A Martin, Vaibhav Katkade, Sujatha Menon, Jean-Baptiste Telliez. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition.
Pharmacology research & perspectives.
2019 12; 7(6):e00537. doi:
10.1002/prp2.537. [PMID: 31832202] - Jayshree Mishra, Randall Simonsen, Narendra Kumar. Intestinal breast cancer resistance protein (BCRP) requires Janus kinase 3 activity for drug efflux and barrier functions in obesity.
The Journal of biological chemistry.
2019 11; 294(48):18337-18348. doi:
10.1074/jbc.ra119.007758. [PMID: 31653704] - Shuang Liu, Chen Li, Ming-Wei Tang, Wen-Shuai Xu, Ke-Qi Chen, Xin Sui, Xin-Lun Tian, Kai-Feng Xu. Improvement of lymphangioleiomyomatosis following successful tofacitinib treatment for refractory synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome.
Chinese medical journal.
2019 Oct; 132(19):2378-2379. doi:
10.1097/cm9.0000000000000441. [PMID: 31503058] - Dafna D Gladman, Christina Charles-Schoeman, Iain B McInnes, Douglas J Veale, Bruce Thiers, Mike Nurmohamed, Dani Graham, Cunshan Wang, Thomas Jones, Robert Wolk, Ryan DeMasi. Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long-Term Extension Studies.
Arthritis care & research.
2019 10; 71(10):1387-1395. doi:
10.1002/acr.23930. [PMID: 31112005] - Katie Bechman, Sujith Subesinghe, Sam Norton, Fabiola Atzeni, Massimo Galli, Andrew P Cope, Kevin L Winthrop, James B Galloway. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis.
Rheumatology (Oxford, England).
2019 10; 58(10):1755-1766. doi:
10.1093/rheumatology/kez087. [PMID: 30982883] - Rujia Xie, Chenhui Deng, Qiang Wang, Keith S Kanik, Timothy Nicholas, Sujatha Menon. Population pharmacokinetics of tofacitinib in patients with psoriatic arthritis
.
International journal of clinical pharmacology and therapeutics.
2019 Sep; 57(9):464-473. doi:
10.5414/cp203516. [PMID: 31319908] - Diana S Novikova, Helen V Udachkina, Eugenia I Markelova, Irina G Kirillova, Anna S Misiyuk, Natalia V Demidova, Tatiana V Popkova. Dynamics of body mass index and visceral adiposity index in patients with rheumatoid arthritis treated with tofacitinib.
Rheumatology international.
2019 07; 39(7):1181-1189. doi:
10.1007/s00296-019-04303-x. [PMID: 31053871] - Qian Qiu, Qilin Feng, Xueying Tan, Mingxing Guo. JAK3-selective inhibitor peficitinib for the treatment of rheumatoid arthritis.
Expert review of clinical pharmacology.
2019 Jun; 12(6):547-554. doi:
10.1080/17512433.2019.1615443. [PMID: 31059310] - Kirtikumar D Bharwad, Priyanka A Shah, Pranav S Shrivastav, Puran Singhal. Development and validation of a rapid and sensitive UPLC-MS/MS assay for the quantification of tofacitinib in human plasma.
Biomedical chromatography : BMC.
2019 Apr; 33(4):e4458. doi:
10.1002/bmc.4458. [PMID: 30520053] - Leopoldo Duailibe Nogueira Santos, Jerry Shapiro. What's New in Hair Loss.
Dermatologic clinics.
2019 Apr; 37(2):137-141. doi:
10.1016/j.det.2018.11.002. [PMID: 30850035] - Foteini Patera, Alex Cudzich-Madry, Zhi Huang, Maria Fragiadaki. Renal expression of JAK2 is high in polycystic kidney disease and its inhibition reduces cystogenesis.
Scientific reports.
2019 03; 9(1):4491. doi:
10.1038/s41598-019-41106-3. [PMID: 30872773] - O Shovman, B Gilburd, A Watad, H Amital, P Langevitz, N L Bragazzi, M Adawi, D Perez, M Lidar, I Katz, M Blank, N K Biln, A Marotta, Y Shoenfeld. Decrease in 14-3-3η protein levels is correlated with improvement in disease activity in patients with rheumatoid arthritis treated with Tofacitinib.
Pharmacological research.
2019 03; 141(?):623-626. doi:
10.1016/j.phrs.2018.11.009. [PMID: 30414892] - Yuxuan Li, Lin Yuan, Jie Yang, Yue Lei, Hui Zhang, Liping Xia, Hui Shen, Jing Lu. Changes in Serum Cytokines May Predict Therapeutic Efficacy of Tofacitinib in Rheumatoid Arthritis.
Mediators of inflammation.
2019; 2019(?):5617431. doi:
10.1155/2019/5617431. [PMID: 31780862] - Stephen Hanauer, Remo Panaccione, Silvio Danese, Adam Cheifetz, Walter Reinisch, Peter D R Higgins, Deborah A Woodworth, Haiying Zhang, Gary S Friedman, Nervin Lawendy, Daniel Quirk, Chudy I Nduaka, Chinyu Su. Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
2019 01; 17(1):139-147. doi:
10.1016/j.cgh.2018.07.009. [PMID: 30012431]